Colorado BioScience Association Announces 2012 BioWest Conference, Unveiling Finalists in the Venture Showcase Competition

Colorado BioScience Association Announces 2012 BioWest Conference, Unveiling Finalists in the Venture Showcase Competition

Colorado BioScience AssociationMae Desaire, 720-382-5918Director of MarketingorAbsolutely Public RelationsMaggie Chamberlin Holben, 303-984-9801

The Colorado BioScience Association (CBSA) announces the 9th BioWest Conference, September 11, 2012, at the Marriott City Center, Denver. The announcement is made by CBSA President & CEO Holli Riebel, who says, “BioWest is the Rocky Mountain region's premier medical device and biotechnology conference and the venue of our much anticipated Venture Showcase competition. We've now selected the six finalists for this year's Venture Showcase and are thrilled by the amazing new technologies that will be presented at BioWest in September."

is developing and commercializing product applications of its proprietary software algorithm platform called CipherSensorTM Technology. The first product application is in the medical trauma setting enabling the immediate, noninvasive detection of the risk for cardiovascular collapse and monitoring of the effectiveness of fluid resuscitation therapy.

- - makes products for analyzing defects and damage to human chromosomes. The company is launching the first commercial platform for the discovery and detection of a recalcitrant class of DNA mutations known as .

- is developing a method for cancer therapy which promises to be safer, with fewer side effects, and at least as effective as current therapies. The company’s approach is precision photothermal treatment of solid tumors using targeted gold nanorods - SivaRods™.

has developed the world’s first non-percutaneous, implantable, bone-anchored hearing device. The company’s Alpha 1 System eliminates the problematic abutment of other devices by using magnets to securely affix the external sound processor to a titanium implant.

is a biotechnology company focused on the discovery and development of small molecule drugs for oncology. The company’s family of compounds target a process crucial for cancer growth but under-utilized as a drug target.

is an emergent veterinary biotechnology company that licenses innovative human biomedical technologies to address serious unmet medical needs in companion animals. The company’s lead candidate is a novel anti-cancer drug.

The finalists pitch their technologies and business plans in front of a live audience at BioWest to a panel of bioscience experts and venture capitalists. The winner, announced at the end of the conference day, will receive a $7,500 cash prize.

The conference features keynote speakers of Harvard Business School and past president of Amylin Pharmaceuticals and former CNBC biopharma and medical device industry reporter-turned-PR pro. The one-day event is attended by more than 500 industry leaders, government representatives, executives, researchers, investors and entrepreneurs. BioWest provides Colorado's bioscience community opportunities to network, learn from one another and collaborate to grow the industry.

Conference Registration is now openat . Early rates for membersstart at $250 and $325 for non-members and passes for the expo hall & reception only are $75 for members and $125 for non-members.Group rates are available for companies and organizations.

Registration for the conference also includes withprograms focusing on Business Development and Clinical Trials; the with over 40 exhibitors showcase new technologies, products and services to attendees; and the featuring Boettcher Investigators in the Webb-Waring Biomedical Research Program to showcase earlier stage technologies from the region’s top research institutions.

include Founders Session SponsorColorado Science + Technology Park at Fitzsimons; Keynote Lunch SponsorErnst & Young ; Venture Showcase Sponsors, Dorsey & Whitney LLP, EKS&H, Metro Denver EDC;Track Sponsors, NextGen, Clinipace, Lonza, Sheridan Ross PC; Lanyard Sponsor, Cooley; Closing Reception Sponsor, Wells Fargo; Co-track Sponsors, University of Colorado Health, National Jewish Health Advanced Diagnostic Laboratories, DaVita Clinical Research; and, General Conference Sponsors, Johnson & Johnson, PhRMA and Fisher Scientific.

The CBSA is a not-for-profit organization providing services and support for Colorado's bioscience industry. With more than 350 members, CBSA actively works to promote the growth of the industry by advocating for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state, and speaking with a single voice on behalf of the industry. For more information, visit .

Twitter:

LinkedIn Group:

Facebook Fan Page:

News Feed:

YouTube Channel:

Pinterest:

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.